Tirzepatide (15mg) Mega 5-pack – save $50

Tirzepatide is a once-weekly injectable medication approved for:

1. Type 2 Diabetes Management: Under the brand name Mounjaro®.

2. Chronic Weight Management: Under the brand name Zepbound®.

It is a significant advancement in the treatment of these conditions and is known for its high efficacy in lowering blood sugar and promoting weight loss.

---

How Does It Work? The “Twincretin” Mechanism

Tirzepatide’s power comes from its unique mechanism of action. It is a single molecule that activates two key hormone receptors in the body, earning it the nickname “twincretin.”

1. GIP (Glucose-dependent Insulinotropic Polypeptide) Receptor Agonist: Tirzepatide is the first medication to activate this receptor.

2. GLP-1 (Glucagon-like Peptide-1) Receptor Agonist: This is the same receptor targeted by other popular drugs like semaglutide (Ozempic, Wegovy).

By acting on both systems, Tirzepatide provides a synergistic effect:

• Stimulates Insulin Secretion: It tells the pancreas to release insulin when blood sugar is high, but does so in a glucose-dependent manner, meaning the risk of low blood sugar (hypoglycemia) is lower when used without other medications like insulin or sulfonylureas.

• Suppresses Glucagon Secretion: It reduces the liver’s production of glucagon, a hormone that raises blood sugar.

• Slows Gastric Emptying: It delays the emptying of the stomach contents into the small intestine. This makes you feel full for longer after eating.

• Reduces Appetite and Food Intake: It acts directly on the brain’s appetite centers to decrease hunger and cravings.

The combined effect on the stomach and brain leads to reduced caloric intake, which is a primary driver of its weight loss benefits.

---

Efficacy: How Well Does It Work?

Clinical trials have demonstrated that Tirzepatide is highly effective, often outperforming other available treatments.

For Type 2 Diabetes (SURPASS Program):

• Blood Sugar Control (A1c Reduction): Patients achieved A1c reductions of 1.8% to 2.6%, with a significant number of patients reaching an A1c below 5.7% (a non-diabetic level).

• Weight Loss: Patients also experienced substantial weight loss, ranging from ~12 to 25 pounds (5.5 to 11.3 kg) on average.

For Weight Management (SURMOUNT Program):

The results here were groundbreaking, leading to its approval for obesity.

• Participants without diabetes lost an average of:

  • 15% of their body weight on the lowest dose (5 mg).

  • 19.5% of their body weight on the middle dose (10 mg).

  • 20.9% of their body weight on the highest dose (15 mg).

• Many individuals lost over 25% of their starting body weight.